Hospital Mortality and Morbidity in Diabetic Patients with COVID-19: A Retrospective Analysis from the UAE.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238455 Publication Model: Electronic Cited Medium: Internet ISSN: 1660-4601 (Electronic) Linking ISSN: 16604601 NLM ISO Abbreviation: Int J Environ Res Public Health Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel : MDPI, c2004-
    • Subject Terms:
      COVID-19*/mortality ; COVID-19*/epidemiology ; COVID-19*/complications ; Hospital Mortality* ; Diabetes Mellitus*/epidemiology ; Diabetes Mellitus*/mortality ; Respiration, Artificial*/statistics & numerical data; Humans ; United Arab Emirates/epidemiology ; Retrospective Studies ; Male ; Female ; Middle Aged ; Aged ; Intensive Care Units/statistics & numerical data ; Adult ; SARS-CoV-2 ; Length of Stay/statistics & numerical data ; Hospitalization/statistics & numerical data
    • Abstract:
      Background: Although we are four years into the pandemic, there is still conflicting evidence regarding the clinical outcomes of diabetic patients hospitalized with COVID-19. The primary objective of this study was to evaluate the in-hospital mortality and morbidity of diabetic versus nondiabetic patients hospitalized with COVID-19 in the Northern UAE Emirates.
      Methods: A retrospective analysis was performed on clinical data from patients with or without diabetes mellitus (DM) who were admitted to the isolation hospital with COVID-19 during the first and second waves of the disease (March 2020 to April 2021). The assessed endpoints were all-cause in-hospital mortality, length of hospitalization, intensive care unit (ICU) admission, and mechanical ventilation.
      Results: A total of 427 patients were included in the analysis, of whom 335 (78.5%) had DM. Compared to nondiabetics, diabetic COVID-19 patients had a significantly longer in-hospital stay (odds ratio (OR) = 2.35; 95% confidence interval (CI) = 1.19-4.62; p = 0.014), and a significantly higher frequency of ICU admission (OR = 4.50; 95% CI = 1.66-7.34; p = 0.002). The need for mechanical ventilation was not significantly different between the two groups (OR: distorted estimates; p = 0.996). Importantly, the overall in-hospital mortality was significantly higher among diabetic patients compared to their nondiabetic counterparts (OR = 2.26; 95% CI = 1.08-4.73; p = 0.03).
      Conclusion: DM was associated with a more arduous course of COVID-19, including a higher mortality rate, a longer overall hospital stay, and a higher frequency of ICU admission. Our results highlight the importance of DM control in COVID-19 patients to minimize the risk of detrimental clinical outcomes.
    • References:
      Crit Rev Clin Lab Sci. 2022 Mar;59(2):93-111. (PMID: 34663176)
      J Clin Endocrinol Metab. 2022 Feb 17;107(3):e1009-e1019. (PMID: 34718627)
      Intensive Care Med. 2007 Mar;33(3):477-84. (PMID: 17260130)
      Infect Dis Clin Microbiol. 2023 Dec 29;5(4):287-291. (PMID: 38633859)
      N Engl J Med. 2020 Apr 30;382(18):1708-1720. (PMID: 32109013)
      Anaesth Crit Care Pain Med. 2020 Aug;39(4):483-485. (PMID: 32660852)
      Emerg Microbes Infect. 2020 Dec;9(1):757-760. (PMID: 32228222)
      Diabetes Care. 2020 Jul;43(7):1378-1381. (PMID: 32409505)
      Prim Care Diabetes. 2022 Feb;16(1):65-68. (PMID: 34857490)
      Lancet Infect Dis. 2020 Oct;20(10):1115-1117. (PMID: 32888409)
      J Diabetes Complications. 2022 Apr;36(4):108145. (PMID: 35148936)
      Front Endocrinol (Lausanne). 2024 Feb 15;15:1287795. (PMID: 38455656)
      Diabetes Metab Syndr. 2020 Jul - Aug;14(4):535-545. (PMID: 32408118)
      Front Med (Lausanne). 2020 May 06;7:199. (PMID: 32435649)
      Clin Microbiol Infect. 2015 May;21(5):474-81. (PMID: 25726038)
      Front Immunol. 2020 Dec 01;11:576818. (PMID: 33335527)
      Int J Environ Res Public Health. 2022 Nov 30;19(23):. (PMID: 36498037)
      PLoS Med. 2022 Jul 19;19(7):e1004052. (PMID: 35853019)
      Front Cardiovasc Med. 2020 Jun 16;7:112. (PMID: 32613010)
      Diabetes Res Clin Pract. 2020 Apr;162:108142. (PMID: 32278764)
      Lancet. 2020 Jul 4;396(10243):63-70. (PMID: 32505220)
      Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-792. (PMID: 32687793)
      Diabetes Obes Metab. 2021 Feb;23(2):589-598. (PMID: 33200501)
      Lancet Diabetes Endocrinol. 2020 Oct;8(10):813-822. (PMID: 32798472)
      China CDC Wkly. 2020 Feb 21;2(8):113-122. (PMID: 34594836)
      Saudi Med J. 2021 Feb;42(2):170-180. (PMID: 33563736)
      Lancet Respir Med. 2020 Sep;8(9):853-862. (PMID: 32735842)
      Front Med (Lausanne). 2023 Apr 17;10:1148334. (PMID: 37138744)
      World J Virol. 2021 Sep 25;10(5):275-287. (PMID: 34631477)
    • Grant Information:
      2021-IRG-MED-3 Deanship of Research and Graduate Studies at Ajman University with the grant reference number: 2021-IRG-MED-3.
    • Contributed Indexing:
      Keywords: COVID-19; SARS-CoV-2; UAE; comorbidities; diabetes; mortality
    • Publication Date:
      Date Created: 20240627 Date Completed: 20240627 Latest Revision: 20240629
    • Publication Date:
      20240629
    • Accession Number:
      PMC11204093
    • Accession Number:
      10.3390/ijerph21060697
    • Accession Number:
      38928943